NEWS
UMASS AMHERST / INSTITUTE FOR APPLIED LIFE SCIENCES
NanoVax was named Judges’ Choice Best Startup at the 19th annual Massachusetts Life Sciences Innovation Day, recognizing its approach to next-generation cancer vaccines.
SCIENCEDAILY / OCTOBER 13, 2025
ScienceDaily highlights UMass Amherst research behind NanoVax’s nanoparticle platform, reporting cancer prevention and immune memory in mouse models.
NEWS-MEDICAL
Coverage of UMass Amherst research showing prevention of melanoma, pancreatic and triple-negative breast cancer in mouse models.
IFLSCIENCE
IFLScience covers experimental nanoparticle cancer vaccine research in mice. The findings are preclinical.
THE INDEPENDENT
The Independent reports on a nanoparticle-based vaccine evaluated against melanoma, pancreatic and triple-negative breast cancer in mice. These findings are preclinical.